Betty Hamilton, MD

Betty Hamilton, MD, assistant professor, Cleveland Clinic, discusses TET2 mutations in molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on allogeneic hematopoietic cell transplant (HCT) outcomes. Hamilton says that determining molecular mutations in patients with AML or MDS is becoming an increasingly powerful tool in determining the proper path of treatment.

Videos

Betty Hamilton, MD, discusses TET2 mutations in molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on allogeneic hematopoietic cell transplant outcomes.

Betty Hamilton, MD | Authors

Articles

Dr. Betty Hamilton on Molecular Mutations in AML and MDS